lobbying_activities: 2684159

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2684159	4094bd0e-dbac-41bb-be1e-29eea35ef496	Q3	MEHLMAN CONSULTING, INC.	284950	THE CAMPAIGN FOR SUSTAINABLE RX PRICING	2021	third_quarter	PHA	S.1391 - Fair Accountability and Innovative Research Drug Pricing Act. Prescription drug pricing issues. Patent abuse issues. Ensuring Innovation Act and the Advancing Education on Biosimilars Act of 2021. Drug-price Transparency for Competition (DTC) Act. The Build Back Better Act, A bill to provide for reconciliation pursuant to title II of the Concurrent Resolution on the Budget for Fiscal Year 2022, S. Con. Res. 14.	Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office	110000		0	0	2021-10-18T10:33:53.350000-04:00